Joelle Guilhot

TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.

TL;DR: A new prognostic score that is superior to the Sokal and Euro scores both in its prognostic ability and in its simplicity is described, which can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention.

TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.

TL;DR: As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML.

TL;DR: Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR, and should be a criterion for resuming therapy.